|
|
| MRD / Regn No. |
: THBC\23-24\08015 |
Date |
: 07/07/2026 |
| Patient Name |
: Moorajmal Santwani |
Age & Gender |
: 61 Yrs. / Male |
| Contact No. |
: 9324728000 |
UHID |
: |
| Ht / Wt / BMI |
: 167 / 79.35 / 28.45 |
BP S / BP D |
: 96 / 62 |
| Allergies |
: NONE |
Referred By |
: |
| |
|
| Problem
List |
: |
T2DM (03/Dec/2001) | HTN (03/Dec/2001) | |
|
Subjective |
: |
T2DM & HTN SINCE 2001,HBA1C IS USUALLY BETWEEN 7-8%,EARLY PARKINSON'S DISEASE ON TREATMENT - DR WADIA ,DOES YEARLY STRESS TEST - DR NANDKUMAR CHONKAR |
|
Objective |
: |
JUN-2026 REPORTS,TC-119.7/ TG-74.1/ LDL-64.7/ HDL-35.8,VITD-35.2/ VITB12-277,T3-100/ T4-7.49/ TSH-3.01,CR-0.91,ALT-39.6/ AST-27.9,EGFR-94,HB13.3,FBS-110.28,HBA1C-7.6,ABF- 121/AL- 154 |
|
Analysis |
: |
OROFER / VIT C,VIT D 2/MTH |
|
Plan |
: |
BALANITIS - NEEDS REGULAR OINTMENT |
|
|
|
S# |
Generic (Trade) Name |
Route |
Dosage |
Usage |
Duration |
|
1 |
RESTYL 0.25MG |
ORAL |
0-0-1 |
AFTER MEAL/ SOS
|
30 DAYS |
|
|
2 |
TABLET GLIMEPIRIDE (1MG) AND METFORMIN (500MG)
GLIMISAVE M1 |
ORAL |
0-0-1 |
BEFORE DINNER
|
4 MTHS |
|
|
3 |
ECOSPRIN AV 75/10 |
ORAL |
0-1-0 |
AL
|
4 MTHS |
|
|
4 |
SAROGLITAZAAR 4 MG
LIPAGLYN 4 MG |
ORAL |
1-0-0 |
ABF
|
4 MTHS |
|
|
5 |
TABLET SITAGLIPTIN (50MG) + METFORMIN (500MG)
ISTAMET 50/500
Medicine For DIABETES |
ORAL |
1-0-1 |
BBF / BD
|
4 MTHS |
|
|
6 |
TABLET TELMISARTAN 20MG
ERITEL 20 MG
Medicine For HTN |
ORAL |
1-0-0 |
ABF
|
4 MTHS |
|
|
7 |
NEXITO 5 MG |
ORAL |
1-0-0 |
ABF
|
4 MTHS |
|
|
8 |
NEBICARD SM |
ORAL |
1/2-0-1/2 |
7 AM / 5 PM
|
4 MTHS |
|
|
9 |
TABLET GLIMEPIRIDE 0.5 MG + METFORMIN 500 MG
GLIMISAVE M 0.5 |
ORAL |
1-0-0 |
BBF
|
4 MTHS |
|
|
10 |
OROFER |
ORAL |
0-1-0 |
3 DAYS A WEEK
|
4 MTHS |
|
|
11 |
NUROKIND OD |
ORAL |
0-1-0 |
3 DAYS A WEEK
|
4 MTHS |
|
|
| |
|
|
|
| Refill :
0 / Substitution: |
|
|
| Education |
: IF LOW SUGARS (<70 MG/DL),TAKE 1 TBSP(15GMS) GLUCOSE POWDER. CHECK AGAIN AFTER 15 MINS IF >100 CAN GIVE A PROTEIN MEAL. |
| Next Visit |
: 07/Nov/2026 |
| Tests Suggested For Next Visit |
: FBS / PPBS / HBA1C > 4 MTHS |
| |
|
| |
|
|
